OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Companyâs segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļOPK
āļāļ·āđāļāļāļĢāļīāļĐāļąāļOPKO Health Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 02, 1995
āļāļĩāļāļĩāđāļCruz (Tony F)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ2997
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļNov 02
āļāļĩāđāļāļĒāļđāđ- -
āđāļĄāļ·āļāļ- -
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻ- -
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ- -
āđāļāļĢāļĻāļąāļāļāđ- -
āđāļ§āđāļāđāļāļāđ- -
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļOPK
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 02, 1995
āļāļĩāļāļĩāđāļCruz (Tony F)
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
Mr. John A. Paganelli
Independent Director
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Dr. Tony F. Cruz, Ph.D.
Chief Executive Officer, Transition Therapeutics, Inc
Chief Executive Officer, Transition Therapeutics, Inc
Dr. Roger J. Medel, M.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
Mr. John A. Paganelli
Independent Director
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
Invesco NASDAQ Future Gen 200 ETF
State Street SPDR S&P Health Care Services ETF
iShares U.S. Healthcare Providers ETF
Goldman Sachs Innovate Equity ETF
iShares MSCI USA Small-Cap Min Vol Factor ETF
iShares Russell 2000 Value ETF
iShares Biotechnology ETF
Invesco RAFI US 1500 Small-Mid ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Invesco NASDAQ Future Gen 200 ETF
āļŠāļąāļāļŠāđāļ§āļ0.53%
State Street SPDR S&P Health Care Services ETF
āļŠāļąāļāļŠāđāļ§āļ0.46%
VanEck Israel ETF
āļŠāļąāļāļŠāđāļ§āļ0.14%
Humankind US Stock ETF
āļŠāļąāļāļŠāđāļ§āļ0.1%
iShares U.S. Healthcare Providers ETF
āļŠāļąāļāļŠāđāļ§āļ0.1%
Goldman Sachs Innovate Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.06%
iShares MSCI USA Small-Cap Min Vol Factor ETF
āļŠāļąāļāļŠāđāļ§āļ0.05%
iShares Russell 2000 Value ETF
āļŠāļąāļāļŠāđāļ§āļ0.04%
iShares Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.04%
Invesco RAFI US 1500 Small-Mid ETF
āļŠāļąāļāļŠāđāļ§āļ0.04%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ